Neurolief

Neurolief is an Israeli neurotechnology company headquartered in Haifa, developing innovative non-invasive neuromodulation solutions for neurological disorders. The company's flagship product, the Relivion system, is a multi-channel transcranial and extracranial neurostimulation device designed for both the acute treatment and prevention of migraine. The device works by simultaneously targeting multiple branches of key cranial nerves, delivering electrical stimulation across several channels to modulate the neural pathways associated with migraine onset and pain. This multi-channel approach differentiates Relivion from single-target neurostimulation devices currently available on the market.

Neurolief has secured $25 million in Series B funding, reflecting strong investor confidence in its technology and clinical direction. The company has advanced its Relivion system through clinical trials, generating evidence supporting its efficacy and safety profile in migraine patients. Its regulatory and development progress positions the company as a meaningful contender in the rapidly growing non-invasive neuromodulation market for headache disorders. The funding will support continued clinical development, regulatory submissions, and commercialization efforts as the company works toward broader market access.

Neurolief represents an important player in the broader neurotech industry at a time when non-invasive brain stimulation is gaining significant clinical and commercial traction. The company's multi-channel stimulation platform addresses an unmet need for drug-free migraine therapies, particularly for patients who are intolerant to or underserved by pharmacological treatments. By combining transcranial and extracranial stimulation in a single wearable device, Neurolief is pushing the boundaries of what non-invasive neurostimulation can achieve therapeutically. Their work contributes to a growing body of evidence that neuromodulation can serve as a viable, scalable alternative to traditional migraine medications.